- A phase II, open-labeled, single-arm study of dose-dense paclitaxel plus carboplatin in advanced or recurrent uterine endometrial cancer treatment: a KCOG-G1303, DOENCA trial
-
Hori K, Nishio S, Ushijima K, Kasamatsu Y, Kondo E, Takehara K, Ito K
- KMID: 2526119
- J Gynecol Oncol.
- 2021 Jul;32(4):e64.
- doi: 10.3802/jgo.2021.32.e64
Objective To determine the safety and efficacy of dose-dense (dd) paclitaxel (PTX) and carboplatin (CBDCA) in treating advanced or recurrent endometrial cancer. Methods Women aged 20–75 years with histologically confirmed endometrial cancer, the... -
- CITED
-
- Close
- SHARE
-
- Close
- Comparison of treatment outcomes of surgery and radiotherapy, including concurrent chemoradiotherapy for stage Ib2-IIb cervical adenocarcinoma patients: a retrospective study
-
Kondo E, Yoshida K, Tabata T, Kobayashi Y, Yamagami W, Ebina Y, Kaneuchi M, Nagase S, Machida H, Mikami M
- KMID: 2536837
- J Gynecol Oncol.
- 2022 Mar;33(2):e14.
- doi: 10.3802/jgo.2022.33.e14
Objective The study compared the treatment outcomes of surgery versus radiotherapy, including concurrent chemoradiotherapy, in stage Ib2–IIb cervical adenocarcinoma patients in Japan. Methods Of 57,470 patients diagnosed with stage I–IV cervical cancer from... -
- CITED
-
- Close
- SHARE
-
- Close
- Randomized phase III trial comparing pegylated liposomal doxorubicin (PLD) at 50 mg/m2 versus 40 mg/m2 in patients with platinum-refractory and -resistant ovarian carcinoma: the JGOG 3018 Trial
-
Motohashi T, Yabuno A, Michimae H, Ohishi T, Nonaka M, Takano M, Nishio S, Fujiwara H, Keiichi K, Kondo E, Sugiyama T, Tabata T
- KMID: 2526299
- J Gynecol Oncol.
- 2021 Jan;32(1):e9.
- doi: 10.3802/jgo.2021.32.e9
Objective: The standard dose for pegylated liposomal doxorubicin (PLD) is 50 mg/m2 every 4 weeks. While 40 mg/m2 has recently been used in clinical practice, evidence supporting this use remains... -
- CITED
-
- Close
- SHARE
-
- Close
- Significance of histology and nodal status on the survival of women with early-stage cervical cancer: validation of the 2018 FIGO cervical cancer staging system
-
Machida H, Matsuo K, Kobayashi Y, Momomura M, Takahashi F, Tabata T, Kondo E, Yamagami W, Ebina Y, Kaneuchi M, Nagase S, Mikami M
- KMID: 2536989
- J Gynecol Oncol.
- 2022 May;33(3):e26.
- doi: 10.3802/jgo.2022.33.e26
Objective To assess the efficacy of the FIGO 2018 classification system for nodal-specific classifications for early-stage cervical cancer; specifically, to examine the impact of nodal metastasis on survival and the effect... -
- CITED
-
- Close
- SHARE
-
- Close
- The post-progression survival of patients with recurrent or persistent ovarian clear cell carcinoma: results from a randomized phase III study in JGOG3017/GCIG
-
Kondo E, Tabata T, Suzuki N, Aoki D, Yahata H, Kotera Y, Tokuyama O, Fujiwara K, Kimura E, Terauchi F, Sumi T, Okamoto A, Yaegashi N, Enomoto T, Sugiyama T
- KMID: 2512059
- J Gynecol Oncol.
- 2020 Nov;31(6):e94.
- doi: 10.3802/jgo.2020.31.e94
Objective: In this study we sought to investigate the clinical factors that affect postprogression survival (PPS) in patients with recurrent or persistent clear cell carcinoma (CCC). We utilized the JGOG3017/Gynecological Cancer... -
- CITED
-
- Close
- SHARE
-
- Close
- Phase 2 single-arm study on the efficacy and safety of niraparib in Japanese patients with heavily pretreated, homologous recombination-deficient ovarian cancer
-
Okamoto A, Kondo E, Nakamura T, Yanagida S, Hamanishi J, Harano K, Hasegawa K, Hirasawa T, Hori K, Komiyama S, Matsuura M, Nakai H, Nakamura H, Sakata J, Tabata T, Takehara K, Takekuma M, Yokoyama Y, Kase Y, Sumino S, Soeda J, Suri A, Aoki D, Sugiyama T
- KMID: 2526354
- J Gynecol Oncol.
- 2021 Mar;32(2):e16.
- doi: 10.3802/jgo.2021.32.e16
Objective: To evaluate the efficacy and safety of niraparib in Japanese women with heavily pretreated ovarian cancer. Methods: This Phase 2 open-label, single-arm study enrolled Japanese women with homologous recombination deficiency-positive... -
- CITED
-
- Close
- SHARE
-
- Close
